Insulin therapy remains the cornerstone of diabetes mellitus management in cats. While newer oral antidiabetic options like SGLT2 inhibitors (Senvelgo and Bexacat) have expanded the veterinary toolkit, many cats—especially those with insulin-dependent diabetes or pre-treated clinical states—rely on daily insulin injections (such as Prozinc or Vetsulin). However, insulin is a high-alert medication where dosing errors, storage issues, or physiological fluctuations can lead to severe adverse outcomes.

To characterize these clinical risks at a population scale, VetMedGuide analyzed the FDA Center for Veterinary Medicine (CVM) public animal adverse-event database using a June 2026 extract (1.34 million reports). We identified 3,614 adverse event reports where the affected animal was a cat and the active ingredient was an insulin preparation (insulin is recorded by active ingredient; brand names are masked in the public data).

The FDA's standard caveat applies throughout: these are spontaneous reports, so they do not establish true event rates or prove that insulin caused any given event. A "report involving insulin" means the drug was being given when the problem was recognized — and insulin is, by definition, given to cats already sick from diabetes — so the data is best read as a population-scale map of where diabetic-cat management breaks down, not as a side-effect rate for the molecule.

The data highlights a significant dual challenge for veterinary teams: the clinical signature is split between glycemic instability and severe hypoglycemia, while a substantial number of events stem from owner administration or storage errors.

The Dual Clinical Signal: Instability vs. Hypoglycemia

When analyzing the reported reactions across all 3,614 feline insulin events, the results reveal two distinct therapeutic failure modes:

Note: Individual reports can contain multiple reactions, so categories are not mutually exclusive. Lethargy combines two coding variants.

1. Glycemic Control Failures

The largest single reaction category is ineffectiveness and loss of glycemic control (1,239 reports), with a further 568 coded as lack of efficacy and 336 as hyperglycemia. This reflects the clinical difficulty of stabilizing diabetic cats, including insulin resistance, rapid metabolism (the Somogyi effect), or underlying concurrent diseases such as pancreatitis, hyperthyroidism, or acromegaly. These are predominantly treatment-failure signals rather than direct drug harm.

2. Acute Hypoglycemia

A total of 743 reports name hypoglycaemia as a reaction. Of those, 106 also recorded a seizure or convulsion — the neuroglycopenic endpoint owners most often miss. Hypoglycemia is a veterinary emergency. Because cats cannot report early adrenergic signs (like hunger or mild anxiety), owners often do not recognize the problem until neuroglycopenic signs—such as ataxia, depression, recumbency, or seizures—occur.

Owner Errors: Dosing, Storage, and Administration

A key finding of this database analysis is the prevalence of preventable, operator-dependent adverse events. The FDA CVM database records several explicit categories of user errors:

• Drug Administration Errors: 50 reports document explicit administration errors. These frequently occur when multiple household members double-dose a cat, or when there is confusion between U-100 and U-40 syringes.
• Incorrect Storage of Drug: 41 reports document storage errors. Insulin is a delicate protein; exposure to extreme temperatures (e.g., freezing or overheating in shipping/home storage) or vigorous shaking can denature the molecule, leading to rapid loss of efficacy and subsequent glycemic spikes.
• Wrong Technique in Drug Usage: 39 reports detail incorrect administration techniques, such as intramuscular instead of subcutaneous injection, or "wet check" errors where a missed injection is repeated, leading to accidental overdose. A further 23 reports coded as overdose and 30 as a medication error round out the preventable-harm picture.

Severity of Outcomes in Feline Insulin Reports

Because insulin-induced hypoglycemia and severe diabetic complications are life-threatening, the outcomes recorded in these spontaneous reports carry a heavy clinical weight. Where outcomes were reported:

• Outcome Unknown: 1,026 cats (28.4%)
• Ongoing/Unresolved: 655 cats (18.1%)
• Recovered/Normal: 604 cats (16.7%)
• Died: 223 cats (6.2%)
• Euthanized: 215 cats (5.9%)

Combined, 438 reports document a fatal outcome (death or euthanasia), representing 12.1% of the total feline insulin caseload reported to the FDA CVM. This high proportion underscores that when insulin management fails or is mismanaged, the margin of safety is narrow.

Clinical Best Practices for Reducing Insulin Risks

Veterinary teams can use these population-scale findings to refine their client counseling and monitoring workflows:

1. Strict Syringe-Insulin Pairing

The mismatch between U-40 and U-100 formulations remains a classic error.

• Prozinc (NADA 141-297): Recombinant human protamine zinc insulin, formulated at U-40 (40 IU/mL). Must be used with U-40 syringes.
• Vetsulin (NADA 141-236): Porcine insulin zinc suspension, formulated at U-40. Must be used with U-40 syringes.
• Lantus/Glargine (Human Label): Formulated at U-100. Must be used with U-100 syringes. Using a U-100 syringe for a U-40 insulin without mathematical correction results in a severe underdose (2.5× less), while using a U-40 syringe for a U-100 insulin results in a massive overdose (2.5× more), triggering severe hypoglycemia.

2. Storage and Handling Protocols

Incorporate storage education into every discharge:

• Always store insulin in the refrigerator between 36°F and 46°F (2°C to 8°C). Never freeze.
• Vetsulin must be shaken vigorously until a homogeneous, milky suspension is obtained. In contrast, Prozinc and Glargine should be rolled gently, not shaken.
• Protect vials and pens from light.

3. Home Monitoring and Early Intervention

Encourage home monitoring using capillary blood glucose meters calibrated for cats (e.g., AlphaTRAK) or continuous glucose monitors (CGM, like the FreeStyle Libre). This allows detection of nadir trends and prevents preemptive dosing when a cat is inappetent or vomiting; see our feline diabetes monitoring guide for the curve, fructosamine, and CGM workflow. If the cat does not eat its full meal, the insulin dose must be adjusted (typically cut in half or skipped entirely, depending on the clinician's guidelines).

Sources

• FDA Center for Veterinary Medicine (CVM), animal adverse-event database (public extract dated June 9, 2026; 1.34 million reports); analysis by VetMedGuide of 3,614 reports naming an insulin active ingredient in cats. The FDA cautions that spontaneous reports do not establish causation or true event rates. https://www.fda.gov/animal-veterinary/safety-health/reporting-animal-drug-and-device-side-effects-and-product-problems
• FDA, Freedom of Information Summary, Original NADA 141-297, PROZINC (protamine zinc recombinant human insulin) for cats, approved October 28, 2009 (U-40 formulation; labeled 0.2–0.7 IU/kg q12h). https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/861
• FDA, Freedom of Information Summary, NADA 141-236, Vetsulin (porcine insulin zinc suspension) for dogs and cats (U-40 formulation). https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/781
• Sparkes AH, Cannon M, Church D, et al. ISFM Consensus Guidelines on the Practical Management of Diabetes Mellitus in Cats. Journal of Feline Medicine and Surgery. 2015;17(3):235-250. doi:10.1177/1098612X15571880